Biotech

The signals I care about are reproducibility of the evidence package, time from milestone to next decision, and readiness for study startup or scale-up. Those metrics reveal whether a team is generating knowledge or only generating slides.

Three metrics worth pressure-testing:
- quality and reproducibility of program evidence
- speed from milestone completion to next decision point
- operational readiness for study startup or expansion

Source material behind the scorecard:
- FDA drug development and approval process: fda.gov/drugs/development-approval-process-drugs
A grounding document for the path from development to review and approval.
- scverse: scverse.org/
A strong starting point for open computational work in modern omics analysis.

If your team has a sharper dashboard, share the metric definitions and the decisions they actually change. That is what makes numbers reusable.